MA33166B1 - Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose - Google Patents
Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibroseInfo
- Publication number
- MA33166B1 MA33166B1 MA33582A MA33582A MA33166B1 MA 33166 B1 MA33166 B1 MA 33166B1 MA 33582 A MA33582 A MA 33582A MA 33582 A MA33582 A MA 33582A MA 33166 B1 MA33166 B1 MA 33166B1
- Authority
- MA
- Morocco
- Prior art keywords
- fibrosis
- treatment
- formula
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title abstract 4
- 230000004761 fibrosis Effects 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne l'utilisation de pyrimidylaminobenzamides de formule (I) où les radicaux ont les significations comme présentement définies, ou d'un sel pharmaceutiquement acceptable de ceux-ci pour la fabrication de compositions pharmaceutiques pour utilisation dans le traitement de la fibrose, l'utilisation de pyrimidylaminobenzamides de formule (I) ou d'un sel pharmaceutiquement acceptable de ceux-ci dans le traitement de la fibrose, un procédé de traitement d'animaux à sang chaud comprenant des humains souffrant de fibrose par administration audit animal nécessitant un tel traitement d'une dose efficace d'un pyrimidylaminobenzamide de formule I ou un sel pharmaceutiquement acceptable de celui-ci, et des combinaisons comprenant (a) au moins un pyrimidylaminobenzamide de formule (I) et (b) au moins un composé choisi parmi des antagonistes de récepteur AT
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08160366 | 2008-07-14 | ||
PCT/EP2009/058940 WO2010007034A1 (fr) | 2008-07-14 | 2009-07-14 | Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33166B1 true MA33166B1 (fr) | 2012-04-02 |
Family
ID=39765085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33582A MA33166B1 (fr) | 2008-07-14 | 2009-07-14 | Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose |
Country Status (17)
Country | Link |
---|---|
US (2) | US20110124670A1 (fr) |
EP (1) | EP2300014A1 (fr) |
JP (1) | JP2011528015A (fr) |
KR (1) | KR20110051194A (fr) |
CN (1) | CN102099039A (fr) |
AU (1) | AU2009272814A1 (fr) |
BR (1) | BRPI0915905A2 (fr) |
CA (1) | CA2730225A1 (fr) |
CL (1) | CL2011000073A1 (fr) |
IL (1) | IL210290A0 (fr) |
MA (1) | MA33166B1 (fr) |
MX (1) | MX2011000511A (fr) |
NZ (1) | NZ590177A (fr) |
RU (1) | RU2011105059A (fr) |
TW (1) | TW201006823A (fr) |
WO (1) | WO2010007034A1 (fr) |
ZA (1) | ZA201009153B (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150098993A1 (en) * | 2011-07-28 | 2015-04-09 | Shireen Vali | Compositions, process of preparation of said compositions and method of treating inflammatory diseases |
JP6177768B2 (ja) * | 2012-04-24 | 2017-08-09 | 中外製薬株式会社 | ベンズアミド誘導体 |
BR112014026305A2 (pt) | 2012-04-24 | 2017-06-27 | Chugai Pharmaceutical Co Ltd | derivado de quinazolidinadiona |
CN103965195B (zh) * | 2013-02-01 | 2016-09-28 | 中国科学院广州生物医药与健康研究院 | 用于盘状结构域受体小分子抑制剂的化合物及其应用 |
CA2927830A1 (fr) | 2013-10-23 | 2015-04-30 | Chugai Seiyaku Kabushiki Kaisha | Derive de quinazolinone et d'isoquinolinone |
CN106282033A (zh) * | 2016-08-15 | 2017-01-04 | 郑毅男 | 一株新青霉菌及其代谢产物安他拟酸a |
KR20210044589A (ko) * | 2019-10-15 | 2021-04-23 | 재단법인 한국파스퇴르연구소 | 2-메톡시에스트라디올 유도체 및 이들의 의약 용도 |
CN115010720B (zh) * | 2022-06-02 | 2023-08-11 | 中国科学院昆明植物研究所 | 中甸艾中倍半萜二聚体及其药物组合物与其制备方法和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2426674A1 (fr) * | 2000-10-25 | 2002-05-02 | Takeda Chemical Industries, Ltd. | Agents pour prevenir ou traiter l'hypertension portale |
DE60308337T2 (de) * | 2002-03-15 | 2007-09-20 | Novartis Ag | 4-(4-Methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyrimidin-3-yl)pyrimidin-2-ylamino)phenylbenzamid zur Behandlung von Ang II vermitteltern Erkrankungen |
CN101035536A (zh) * | 2004-10-08 | 2007-09-12 | 诺瓦提斯公司 | 有机化合物的组合 |
WO2007022041A2 (fr) * | 2005-08-11 | 2007-02-22 | Novartis Ag | Mutations et polymorphismes de l'hdac3 |
WO2007051862A1 (fr) * | 2005-11-07 | 2007-05-10 | Novartis Ag | Combinaison de composés organiques |
US8093259B2 (en) * | 2006-05-25 | 2012-01-10 | Novartis Ag | 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma |
KR20090055595A (ko) * | 2006-08-25 | 2009-06-02 | 노파르티스 아게 | 알도스테론 신타제 및/또는 11-베타-히드록실라제 및/또는 아로마타제에 의해 매개된 장애의 치료를 위한 융합 이미다졸 유도체 |
ES2409756T3 (es) * | 2006-12-04 | 2013-06-27 | Promedior, Inc. | Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos |
EP2094669A2 (fr) * | 2006-12-18 | 2009-09-02 | Novartis AG | Derives d`imidazoles substitues en position 1 et leur utilisation en tant qu`inhibiteurs de l`aldosterone-synthetase |
EA200900812A1 (ru) * | 2006-12-18 | 2009-12-30 | Новартис Аг | Производные 4-имидазолил-1,2,3,4-тетрагидрохинолина и их применение в качестве ингибиторов альдостерон/11-бета-гидроксилазы |
-
2009
- 2009-07-13 TW TW098123638A patent/TW201006823A/zh unknown
- 2009-07-14 US US13/054,011 patent/US20110124670A1/en not_active Abandoned
- 2009-07-14 EP EP09797487A patent/EP2300014A1/fr not_active Withdrawn
- 2009-07-14 BR BRPI0915905A patent/BRPI0915905A2/pt not_active IP Right Cessation
- 2009-07-14 RU RU2011105059/15A patent/RU2011105059A/ru unknown
- 2009-07-14 WO PCT/EP2009/058940 patent/WO2010007034A1/fr active Application Filing
- 2009-07-14 KR KR1020117003226A patent/KR20110051194A/ko not_active Application Discontinuation
- 2009-07-14 CA CA2730225A patent/CA2730225A1/fr not_active Abandoned
- 2009-07-14 MX MX2011000511A patent/MX2011000511A/es not_active Application Discontinuation
- 2009-07-14 CN CN2009801273499A patent/CN102099039A/zh active Pending
- 2009-07-14 NZ NZ590177A patent/NZ590177A/xx not_active IP Right Cessation
- 2009-07-14 AU AU2009272814A patent/AU2009272814A1/en not_active Abandoned
- 2009-07-14 JP JP2011517892A patent/JP2011528015A/ja active Pending
- 2009-07-14 MA MA33582A patent/MA33166B1/fr unknown
-
2010
- 2010-12-20 ZA ZA2010/09153A patent/ZA201009153B/en unknown
- 2010-12-27 IL IL210290A patent/IL210290A0/en unknown
-
2011
- 2011-01-13 CL CL2011000073A patent/CL2011000073A1/es unknown
-
2013
- 2013-06-06 US US13/911,127 patent/US20130267549A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2010007034A1 (fr) | 2010-01-21 |
CN102099039A (zh) | 2011-06-15 |
US20130267549A1 (en) | 2013-10-10 |
CL2011000073A1 (es) | 2011-07-15 |
KR20110051194A (ko) | 2011-05-17 |
BRPI0915905A2 (pt) | 2018-02-20 |
US20110124670A1 (en) | 2011-05-26 |
TW201006823A (en) | 2010-02-16 |
CA2730225A1 (fr) | 2010-01-21 |
JP2011528015A (ja) | 2011-11-10 |
EP2300014A1 (fr) | 2011-03-30 |
MX2011000511A (es) | 2011-02-24 |
IL210290A0 (en) | 2011-03-31 |
AU2009272814A1 (en) | 2010-01-21 |
NZ590177A (en) | 2012-12-21 |
ZA201009153B (en) | 2011-11-30 |
RU2011105059A (ru) | 2012-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33166B1 (fr) | Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose | |
RU2370495C2 (ru) | Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора | |
MA31352B1 (fr) | Dérivés imidazolidine carboxamide comme modulateurs de p2x7. | |
EA201000024A1 (ru) | Новые производные дикарбоновых кислот в качестве агонистов рецептора s1p1 | |
MA37834A1 (fr) | Analogues de pyridazine 1,4-disubstituée et procédés de traitement de troubles liés à une déficience en smn | |
EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
EP1857457A3 (fr) | Dérivé de benzimidazole et son utilisation comme antagoniste du récepteur AII | |
MXPA05011166A (es) | Antagonistas del receptor del peptido relacionado con el gen de la calcitonina. | |
MA31766B1 (fr) | Composés organiques | |
MA34898B1 (fr) | Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques | |
MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
WO2009106980A3 (fr) | Dérivés d'indazole | |
ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
MA38315A1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
MA34650B1 (fr) | Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane | |
MA32009B1 (fr) | Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux | |
MA30798B1 (fr) | Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1 | |
EA201001094A1 (ru) | Производные индазола | |
NO20071314L (no) | Peptidiske vasopressinreseptoragonister | |
MA35271B1 (fr) | Antagonistes de trpm8 et leur utilisation dans des traitements | |
MXPA05008142A (es) | Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension. | |
NO20073170L (no) | Kaspaseinhibitorer og anvendelse derav | |
MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique |